Yan Yin Tech

Yan Yin Tech (衍因科技, formally Shanghai Yanyin Technology Co.) is an AI-for-biotech company founded and led by CEO Dr. Chen Zeping (陈泽平), backed by Qiming Venture Partners with an angel round in the tens of millions of yuan . Its core product is "衍因智研云" (Yanyin Zhiyan Cloud), an enterprise-grade life-science research collaboration platform built on AI large models, including an "AI translation agent" purpose-built for biopharma . Through 2025 it moved visibly on the partnering front: it co-developed China's first CRISPR gene design tool with ZhuanMa Bio , signed strategic collaborations with Epigenic Therapeutics, HEC Pharm, and Huanma Bio (a three-year deal) , and teamed up with Evolutionary Tide (演生潮) on drug R&D for acquired immune dysregulation . Note the coverage here comes entirely from Qiming Venture Partners' portfolio updates in 2025, so it's a view through its investor's lens rather than independent reporting.